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Antineoplastic activity of taurolidine and its derivatives on
human ex vivo glioblastoma bulk cells and cancer stem cells
Abstract
Despite multimodal therapy, patients suffering from glioblastoma (GBM) still have a dismal prognosis.
The identification of cancer stem cells (CSC) in brain tumour tissue, yielded hope that the vulnerable
target to combat GBM has been found. Several study groups worldwide concentrate nowadays on
therapeutic strategies that effectively target CSC. Since in our laboratory has been revealed that
taurolidine, a derivate of the amino acid taurin, displays a potent antineoplastic effect in human glioma
cell lines and in ex vivo malignant cell culture, this thesis focused on the susceptibility of glioblastoma
CSC to taurolidine and temozolomide (TMZ), the most commonly used chemotherapeutic agent so far.
Additionally, we investigated the most powerful derivative of taurolidine and tested its antineoplastic
activity on CSC as well.
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 Abbreviations 
 
BTSC  brain tumour stem cells 
CSC  cancer stem cells 
CXCR1  IL-8 receptor 
EGF  epidermal growth factor 
FasL  Fas ligand 
FCS  fetal calf serum 
FGF  fibroblast growth factor 
GBM  glioblastoma multiforme 
HBSS  Hank’s bilance salt solution 
LIF  leukemia inhibitory factor 
MGMT  methyl-guanine methyl transferase gen 
NAC  N-acetyl-L-cysteine 
NCS  neural stem cell 
ROI  reactive oxygen intermediates 
SCID  severe combined immunodeficiency  
TMZ  temozolomide 
TT  taurultam 
Z-VAD-FMK  pan-caspase inhibitor 
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 1. Summary 
 
Objective: Despite multimodal therapy, patients suffering from glioblastoma (GBM) still have 
a dismal prognosis. The identification of cancer stem cells (CSC) in brain tumour tissue, 
yielded hope that the vulnerable target to combat GBM has been found. Several study 
groups worldwide concentrate nowadays on therapeutic strategies that effectively target 
CSC. Since in our laboratory has been revealed that taurolidine, a derivate of the amino acid 
taurin, displays a potent antineoplastic effect in human glioma cell lines and in ex vivo 
malignant cell culture, this thesis focused on the susceptibility of glioblastoma CSC to 
taurolidine and temozolomide (TMZ), the most commonly used chemotherapeutic agent so 
far. Additionally, we investigated the most powerful derivative of taurolidine and tested its 
antineoplastic activity on CSC as well.  
Methods: Studies were performed using different glioblastoma cell lines and isolated ex vivo 
glioblastoma cell cultures. CSC were isolated from tumour tissue by the use of neurosphere 
culture conditions. We investigated the antineoplastic potential of taurolidine, its eight 
derivates and TMZ on these cells by performing cytotoxicity assays.  
Results: Our findings revealed that all tested glioblastoma CSC were sensitive to taurolidine 
and taurultam (TT). TT was the most powerful taurolidine derivate of the eight ones tested. 
The mean EC50 of taurolidine was 13 ± 2 g/ml and the mean EC50 of TT was 11 ± 0.9 g/ml, 
both in the range of the measured plasma level of patients treated with taurolidine. In 
contrast, the mean EC50 of TMZ was 69 ± 26 g/ml, 5-fold higher than its peak plasma level. 
Conclusion: Targeting and eliminating CSC is a prerequisite to improve outcomes for GBM 
patients. According to our findings that CSC are sensitive to taurolidine and its most powerful 
derivative TT, both of them are promising new therapeutic agent in the GBM therapy and 
should be investigated in a clinical trial.  
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 2. Introduction 
 
The most frequent primary brain tumours in adults are gliomas [1]. Amongst them, 
glioblastoma multiforme (GBM) are the most common and, due to its invasiveness and 
propensity for recurrence, the most malignant tumours. Despite optimal treatment and 
intensive ongoing research, the outcome remains poor. The median survival is only 12 to 15 
months [2] and the 2-year survival rate is 10-25% [3]. The identification of cancer stem cells 
(CSC) in human brain tumours by Singh and his colleagues [4], yielded hope that the 
vulnerable target to combat GBM has been found. CSC are defined as a small subpopulation 
of tumour cells, which are able to self-renew, proliferate and generate tumours [3]. Several 
study groups worldwide focus now on therapeutic strategies that effectively target CSC. It is 
essential to overcome their resistance to radio- and chemotherapeutics if glioblastomas shall 
be completely eradicated [2]. 
 
 
2.1 Glioblastoma multiforme 
2.1.1 Epidemiology 
 
The annual incidence of malignant gliomas is approximately 5 cases per 100.000 people. 
GBM account for approximately 60 to 70% of malignant gliomas, anaplastic astrocytomas for 
10 to 15%, and anaplastic oligodendrogliomas for 10%, less common tumours account for 
the rest. The incidence has increased slightly over the past two decades, primarily as a result 
of improved diagnostic imaging. The median age of patients at the time of diagnosis is 64 
years and men are more frequently affected than women (sex ratio 3:2) [2, 5]. 
 
2.1.2 Etiology 
 
No underlying cause has been identified for the majority of malignant gliomas. The only 
established risk factor is exposure to high doses of ionizing radiation.  An association with 
head injury, occupational risk factors or exposure to electromagnetic fields couldn’t be 
proved. 5% of patients with malignant gliomas have a family history of gliomas. Some of 
these familial cases are associated with rare genetic syndromes, such as neurofibromatosis 
types 1 and 2, the Li-Fraumeni syndrome and Turcot’s syndrome. Nonetheless, most familial 
cases have not an identified genetic cause [2]. 
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 Glioblastoma multiforme either develop de novo (primary GBM>90%) or by progression from 
low-grade or anaplastic astrocytomas (secondary GBM = 5-10%) [5]. 
 
2.1.3 Localization and tumour growth  
 
The most common localization is the deep white matter of the cerebral hemispheres, 
particularly in the frontotemporal regions. Due to its infiltrative growth, GBM rapidly extends 
into the cortex or the basal ganglia causing clinical symptoms. As it can across the corpus 
callosum into the contralateral hemisphere, it is also termed butterfly glioma. GBM of the 
brainstem, cerebellum or spinal cord hardly occur [5]. 
Although extremely malignant, extra-cranial metastasis from GBM are quite rare with an 
incidence of <2% reported in the published literature. In general, they are asymptomatic or 
are found only at autopsy. Factors contributing to the limited incidence of metastatic disease 
include the dense impassable dura, the unique extracellular matrix of the brain, the tough 
basement membrane that surrounds intracerebral blood vessels, the lack of true lymphatic 
vessels and limited patient survival. The regional extension and less frequently lepto-
meningeal dissemination are the main causes of death [1].  
 
2.1.4 Clinical findings 
 
Four main circumstances lead to arise the presumptive diagnosis. First, patients have partial 
or generalised seizures. Second, raised intracranial pressure caused by vasogenic edema 
provokes headache, nausea, vomiting, drowsiness and visual abnormalities (diplopia due to 
abducens-nerve palsy). Classic headaches that are suggestive of increased intracranial 
pressure are most severe in the morning and may awake the patient from sleep [2]. Third, 
progressive focal neurological deficits generally show the tumour side. Supratentorial 
tumours induce motor- or sensitive deficits while posterior fossa tumours are associated with 
various combinations of cranial-nerve palsies, cerebellar dysfunction and long-tract signs. 
Finally, cognitive dysfunction of variable severity represents the frontal or diffuse brain 
infiltration [1]. 
Patients with a de novo GBM normally present with a short clinical history whereas 
secondary GBM patients have in general a clinical history over years.  
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 2.1.5 Histology 
 
Analysis of the most malignant region of the tumours permits grading dependent on main 
features such as high cellularity, pleomorphism, nuclear atypia, mitoses, microvascular 
proliferation and necrosis [1]. On the basis of these histological features, the World Health 
Organization classifies astrocytomas into four prognostic grades: pilocytic astrocytomas 
(grade I), diffuse astrocytomas (grade II), anaplastic astocytomas (grade III) and 
glioblastoma multiforme (grade IV), which is the most frequent subtype [2]. 
Macroscopically, GBM appears poorly delineated, with greyish vital and yellowish necrotic 
areas. Multiple areas of old and recent haemorrhages are also typical [5]. 
 
2.1.6 Radiographic findings 
 
Magnetic resonance imaging (MRI), with and without gadolinium infusion, is the imaging 
technique of choice when a brain tumour is clinically suspected [1]. There, GBM typically 
presents as heterogeneously enhancing mass with surrounding edema. Glioblastomas 
frequently have central areas of necrosis and extensive peritumoral edema [2]. Mass effect in 
form of a midline shift, caused by the rapidly growing tumour, is very often seen [5]. If no MRI 
is available, CT scanning, although less sensitive than MRI, is appropriate to obtain a quick 
assessment of the lesion [1]. Further imaging techniques as functional MRI or diffusion-
weighted imaging are increasingly used as diagnostic aids and to monitor the response to 
therapy [2]. 
However, imaging patterns are not specific and diagnosis must be confirmed by histological 
examination of tumour biopsy samples or by surgical resection. As morphological 
assessment might be confusing, it is important that clinical, radiological and pathological data 
are in accordance [1]. 
 
2.1.7 Therapy and prognosis 
 
General management 
Glioblastomas are still incurable and the aim of the palliative treatment is to improve 
neurological deficits and to increase survival while maintaining the best possible quality of 
life. Much of the care of patients with GBM involves general medical management and 
psychological support. The most common problems include seizures, peritumoural edema, 
venous thromboembolism, fatigue, cognitive dysfunction and depressions. Patients 
presenting seizures should be treated with antiepileptic drugs. Since they can have negative 
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 interference with chemotherapy, a strict indication is essential. To treat peritumoural edema, 
corticosteroids are frequently used. Because of their multiple side-effects and their influence 
on chemotherapy, only the minimum efficient dose should be prescribed. While the patients 
have an increased incidence of venous thromboembolism from leg and pelvic veins, they 
sould get anticoagulation therapy assuming there is no contraindication such as intracerebral 
hemorrhage. Depression is underdiagnosed in patients with malignant gliomas and 
antidepressants and psychiatric support are often invaluable. Rehabilitation, including 
physical therapy, should not be discouraged by a presumed poor outlook [1] [2].  
 
Specific management 
The standard therapy for newly diagnosed GBM involves maximal surgical resection, 
radiotherapy and chemotherapy. Surgical debulking reduces the symptoms from mass effect 
and provides tissues for histological diagnosis. Due to their infiltrative nature, GBM cannot be 
completely eliminated surgically. Therefore, adjuvant radiotherapy and chemotherapy are 
essential. The addition of radiotherapy to surgery increases survival from a range of 3 to 4 
months to a range of 7 to 12 months. Chemotherapy is assuming an increasingly important 
role in the treatment of malignant gliomas. Recent research results demonstrated that the 
most successful adjuvant therapy for newly diagnosed GBM consists of a radio - and 
chemotherapy with temozolomide (TMZ): TMZ is given concomitantly with radiotherapy, 
followed by six monthly cycles of TMZ. Despite continued advances in surgical and medical 
therapies, prognosis with a 5 year mortality rate of close to 100% remains dismal and further 
improvements are desperately needed [2] [5]. 
 
 
2.2 Cancer stem cells 
2.2.1 History 
 
A study of leukaemia was the first to report that a specific subpopulation of leukemic cells 
was capable of initiating human AML after transplantation into SCID mice. These SCID 
leukaemia-initiating cells (CD34+/CD38-) posses differentiative and proliferative capacities 
and the potential of self-renewal that are not present in the majority of leukemic cells [6, 7]. 
Furthermore, it was shown that this subpopulation is necessary and sufficient to generate or 
maintain the tumour population [6].  
Meanwhile similar CSC have been described for a wide variety of solid tumours including 
brain tumours, breast cancer, bone sarcoma, colon cancer, liver cancer, lung cancer, and 
melanoma [3, 6]. 
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 2.2.2 Brain tumour stem cells (BTSC) 
 
In 2003, the identification and purification of CSC from human brain tumours that posses a 
marked capacity for proliferation, self-renewal and differentiation was described by Singh and 
colleagues [4]. BTSC was isolated by selecting cells expressing the neural stem cell surface 
marker CD133. These CD133+ cells could differentiate in vitro into tumour cells that 
phenotypically resembled the tumour from the patient. The self-renewal capacity of tumour 
cells was only present in the CD133+ fraction. The authors suggested there is coherence 
between the self-renewal capacity of the brain tumour stem cells and the increased 
malignancy. Injection of as few as 100 CD133+ cells into mice produced a tumour, whereas 
injection of 105 CD133- could not induce any tumour progression [3]. 
Concomitantly Galli and his colleagues reported an alternative strategy based on the 
neurosphere assay to isolate BTSC [8]. They found that cells dissociated from human brain 
tumour tissue proliferate and expand exponentially under the culture conditions used to grow 
normal neurospheres [3]. It has further been proved by Liu and others that the percentage of 
CD133+ was significantly elevated in recurrent gliomas than that in autologous primary 
tumour tissue [9]. 
A BTSC is defined as follows: a cell must be able to 1) generate clonally derived cells that 
form neurospheres 2) self-renew and proliferate 3) differentiate and express typical markes 
of brain cells 4) induce tumours after in vivo transplantation in animal models that are similar 
to the donor patient’s original tumour [6]. 
 
2.2.3 Origin of brain tumour stem cells 
 
The cell origin of brain tumours remains a subject of ongoing debate in the current scientific 
literature [10]. Two main hypotheses coexist: 1) brain tumours arise from the transformation 
of a normal stem cell (NSC) or 2) brain tumours arise from the dedifferentiation of a mature 
brain cell due to genetic alterations (see Fig. 1) [6]. There is, however, evidence to support a 
combined role for NSC transformation and dedifferentiation of neuroepithelial precursor cells 
[3]. On one side several lines of evidence suggest that brain tumours arise from the 
transformation of a normal NSC, all of which rely on the recognition of the many functional 
and genetic similarities shared by somatic stem cells and cancer cells. Furthermore, brain 
tumours can be very heterogeneous, being comprised of cells expressing phenotypes of 
more than one neural lineage, implicating a multipotential cell of origin. On the other side, 
there exist data supporting that dysregulation of specific genetic pathways, rather than cell of 
origin, may dictate the emergence and phenotype of high-grade gliomas. In summary, a NSC 
may be seen as a more likely compartment for transformation, since its self-renewal 
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  11
machinery is already primed and it has a long lifespan favouring the accumulation of 
mutations [10].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. On the left, normal neural stem cells in the brain undergo highly regulated self-renewing 
divisions to regenerate themselves. In addition, they also generate lineage-committed progenitor cells 
and then differentiate into the three main neural lineages, neurons, astrocytes and oligodendrocytes. 
On the right, multiple mutation events target a stem cell, progenitor cell or mature brain cell resulting in 
the formation of a BTSC (see Ref. [10]) 
 
2.2.4 Therapeutic impact 
 
The fact that a small population of highly potent cells allows the tumour to grow, might 
explain the recurrence of some brain tumours after surgery, chemotherapy and radiation 
therapy. These treatment failures are nowadays seen as the persistence of CSC [3]. 
Different mechanism underlying CSC chemo- and radiorestistance have been postulated [3] 
[11] [12]. Radioresistance in stem cells mainly results from the preferential activation of DNA-
damage-response pathways, whereas chemoresistance results from the overexpression of 
MGMT, the up-regulation of multidrug resistance genes, and the inhibition of apoptosis [2]. 
Therefore new therapeutic research should focus on the eradication of CSC, increasing their 
sensitivity to chemotherapy and radiation therapy.  
 2.3 Temozolomide 
2.3.1 Features of temozolomide 
 
Temozolomide (TMZ) is the most commonly used chemotherapeutic agent in the therapy of 
GBM. In 2005, Stupp and colleagues proved that the addition of TMZ to radiotherapy after 
debulking surgery resulted in a clinically meaningful and statistically significant survival 
benefit [13]. They reported that the combination of radiotherapy and TMZ compared with 
radiotherapy alone increases the median survival (14.6 months vs 12.1 months) and the 2-
year survival rate (27% vs 10%). Recently, these authors published long-term results from 
their research proofing the survival advantage of combined treatment but also confessing 
that long time survivors are still rare [14]. 
 
TMZ achieves its cytotoxic effect mainly by methylating the O6 position of guanine, which 
mismatch with thymine leading to cancer cell death [9] [15]. The DNA repair protein O6-
methylguanine-DNA-methyltransferase (MGMT) can remove O6-methylguanine. MGMT is 
only expressed in a subgroup of GBM. Therefore, TMZ receives its highest efficacy against 
tumours lacking MGMT expression due to a methylated MGMT promoter [16]. It is of note 
that on genetic modification of the MGMT in the course of tumour development results in 
increased susceptibility in about 20% of the patients [17]. So the MGMT promoter 
methylation is not only a prognostic marker, but also a predictive marker for response to 
TMZ. This molecular marker could become in future an indicator for treatment decision [18].  
 
2.3.2 The effect of temozolomide on CSC  
There are controversial findings of TMZ on CSC. Beier and others found that TMZ 
preferentially eliminates CSC but spares more differentiated tumour cells [16] whereas Liu 
and colleagues reported that CD133+ cells had significant resistance to TMZ compared to 
CD133- cells due to higher MGMT expression in CD133+ cells [9]. 
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 2.4 Taurolidine  
2.4.1 Features of taurolidine  
 
Taurolidine is originally developed in the 1970s by Geistlich-Pharma AG (Wolhusen, 
Switzerland). It is chemically identified as Bis-(1,1-dioxoperhydro-1,2,4-thiadiazinyl-4) 
methane and represents a derivative of the amino acid taurin [5]. 
Taurolidine has been shown to exhibit antimicrobial and antiadherence properties [19]. 
Clinically, taurolidine is established as an antimicrobial agent and mainly used as an 
antibacterial lavage in abdominal surgery to reduce postoperative infection or postoperative 
peritoneal adhesion. It is also used to treat local or diffuse peritonitis [5]. Its mechanism as an 
antibiotic agent seems to be related to a chemical reaction between the active taurolidine 
breakdown products and structures on the wall of bacteria, resulting in disruption of bacterial 
cell wall and bacterial cell adhesion. In addition, it neutralizes endotoxins and 
lipopolysaccarides released by bacteria. The ability of taurolidine to affect cell surface 
structures and function explains its antiadherence properties [20]. 
Recently, at doses considerably lower than required for bactericidal activity, taurolidine was 
found to posses also antineoplastic and antiangiogenic activities [19]. The significant and 
selective antineoplastic activity has been proved for several human tumour cell lines as 
GBM, colon, lung, ovarian, prostate and melanoma [5] [20]. The antineoplastic effect of 
taurolidine is not only attributed to classic apoptosis, but also to other death pathway 
mechanism. Our previous studies revealed that taurolidine-induced cell death was induced 
by the formation of reactive oxygen intermediates (ROI) which were abolished by the radical 
scavenger N-acetyl-L-cysteine, but not by the pan-caspase inhibitor Z-VAD-FMK [19]. 
Stendel, et al could demonstrate that through induction of oxidative stress more than one cell 
death mechanism is involved, naming different caspase-independent programmed cell death 
pathways such as autophagy, senescene, necroptosis and necrosis [21]. The antiangiogenic 
ability is due to the potential of taurolidine to decrease the amount of secreted vascular 
endothelial growth factor (VEGF) by the tumour cells. As VEGF is said to be a critical 
regulator of tumour expansion and neovascularization, taurolidine could suppress tumour cell 
growth by its combined antineoplastic and antiangiogenic effects [19].  
 
2.4.2 Features of the derivatives of taurolidine  
 
As shown in Figure 2, taurolidine is broken down into taurinamide and finally, into taurin and 
water with reactive methylol groups being formed as intermediates [19]. The derivatives have 
been produced, purified and provided by Geistlich-Pharma AG.  
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 They are coded in the following manner:  
 TT = Taurultam  E1234  
 2012 = Dimethyltaurultam  2240  
 GS208 = N-Methyltaurultam  1183A 
 HG 40   1183BX  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Simplified scheme of the formation of some derivates of taurolidine. [22] 
 
Considering the high antineoplastic activity of taurolidine on human glioma cell lines, we 
decided to investigate all the intermediates on their antineoplastic properties. Thus, the main 
goal of this study was to find the most powerful derivate of taurolidine regarding the fact that 
isolating the responsible intermediates could reduce the clinical side effects of taurolidine. As 
the chemo- and radioresistance of CSC is seen to be responsible for the treatment failures, 
our further interest focused on the effect of taurolidine and its derivatives on CSC.  
 
 
We first performed cytotoxicity assays after 24 and 48 hours of exposure to taurolidine and 
its derivatives on several human glioma cell lines and ex vivo glioblastomas. From our 
previous studies we knew that taurolidine induces cell death through the generation of 
reactive oxygen intermediates (ROI). We elucidated that the most powerful derivate TT 
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 performed cell death by ROI induction. Because we were interested in the effect of 
taurolidine and TT on CSC, we tested in addition their cytotoxicities on mouse and human 
CSC. We also included TMZ, the most commonly used chemotherapeutic agent in the GBM 
therapy, in our investigations. Based on earlier findings that GBM and glioma cell lines 
express IL-8 and their corresponding receptors [23] and a recent report [24] showing that on 
anti-CXCR1 antibody induces cell death, we tested the blockage of IL-8 receptor (CXCR1) by 
an anti-CXCR1 antibody on CSC survival and the CSC initating capacity by the addition of 
recombinant IL-8. 
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 3. Material and Methods 
3.1 Reagents 
Taurolidine stock solution of 20 mg/ml and its derivatives (2012, GS208, TT, HG40, E1324, 
2240, 1183A, 1183BX) ultrapure powder were kindly provided by Dr. R. Pfirrmann (Geistlich 
Pharma AG, Wolhusen, Switzerland). For each experiment dilution series were freshly 
prepared in complete tissue culture medium at final concentrations ranging from 3.125 to 800 
g/ml. Before their use they were sterile filtered (0.22m Acrodisc filter). 
N-acetyl-L-cysteine (NAC), TMZ and crystal violet were purchased from Sigma Aldrich 
(Buchs, Switzerland). Z-VAD-FMK was bought from BioVision (Mountain View, CA, USA). 
Mega FasL was purchased by Apoxis SA (Lausanne, Switzerland). Recombinant IL-8 was 
obtained by PeproTech (Hamburg, Germany) and anti-CXCR1 antibody was purchased by 
R&D Systems (Minneapolis, USA).  
 
3.2 Cell lines 
The human glioma cell lines LN229, U373, LN18, U251 and U87G were kindly provided by  
Prof. N. de Tribolet (Geneva, Switzerland). T98G was obtained by American Type Culture 
Collection (Rockville, MD, USA). SMA 560 cells were kindly provided by Prof. D. D. Bigner 
(Durham, NC). The cells were cultured as monolayers in 75 cm2 flasks (TPP, Trasadingen, 
Switzerland) in Dubecco modified Eagle’s medium (DMEM, GIBCO, Invitrogen AG, Basel, 
Switzerland) containing 5% fetal calf serum (GIBCO), 2 mM N-acetyl-L-alanyl-L-glutamine 
(Biochrom, Berlin, Germany) and 20 g/ml gentamycin (GIBCO) and maintained at 37°C in a 
92% air/8% CO2 humidified atmosphere. Cells were detached and splitted by using Trypsin-
EDTA (GIBCO).  
 
3.3 Patients 
Human high grade gliomas were acquired from 6 patients undergoing surgery for brain 
tumour resection at the University Hospital Zurich, Switzerland. All tumour samples were 
high grade gliomas WHO Grade IV, all of them newly diagnosed. The diagnoses were 
confirmed at the Institute of Neuropathology, University Hospital Zurich. The median age of 
the patients was 54 ± 10 years (range 36-66 years) with a 4:2 male/female distribution. For 
all assays with ex vivo gliomas early passages of cultures (1-15) were used.  
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 3.4 Dissociation of brain tumours  
After tumour removal, tissues were immediately placed in petri dishes, minced mechanically 
in HBSS (GIBCO), and digested enzymatically by adding collagenase/dispase (Roche 
Applied Science, Rotkreuz, Switzerland) and DNase. For 1 hour this mixture was left on a 
magnetic stirrer in a 37° water bath. Thereafter, the dissociated cells are sequentially filtered 
through 70- and 100 m cell strainers (BD Falcon, BD Biosciences, Basel, Switzerland) to 
remove any tissue debris. Erythrocytes were removed by resuspending and incubation the 
cells in ACK buffer (17 mM Tris-HCl [ph 7.2] containing 144 mM NH4Cl) for 10 minutes at 
room temperature. The cells are washed in HBSS and after counting placed in culture.  
The isolated tumour cells were either cultured as bulk in the same medium as described 
above or in neurosphere conditions using neurobasalmedium (GIBCO) containing 2% B-27 
(GIBCO), 2 mM N-acetyl-L-alanyl-L-glutamine (Biochrom), 50 g/ml gentamycin (GIBCO), 
3.2 U/ml Heparin (Sigma Aldrich), 0.02 g/ml EGF (PeproTech), 0.02 g/ml FGF 
(PeproTech) and 2 ng/ml LIF (Sigma Aldrich). Only CSC survived in flasks containing 
neurobasalmedium. The bulk cells were cultivated in the same medium (DMEM) as used for 
human glioma cell lines.  
 
3.5 Cytotoxicity assay 
Tumour cells were cultivated as monolayers in 75 cm2 flasks containing cell culture medium 
(see above). They were incubated at 37° until they were confluent for more than 80%. Then 
cells were washed with HBSS and separated by adding Trypsin-EDTA for 5 min. After 
centrifugation, dissolution with medium and cell counting, a suspension of 20 x 105 cells/ml 
was prepared. 20.000 cells per well were distributed in 100 l to 96-well F-plates (BD 
Falcon). After overnight culture, the cells reached a confluence of 80% and were treated with 
taurolidine and its derivates. Therefore, taurolidine and each of its derivatives 2012, GS208, 
TT, HG40, E1234, 2240, 1183A, 1183BX were freshly prepared for each experiment at a 
concentration of 800 g/ml. The solution was sterile filtred and further titrated to final 
concentrations of 400, 200, 100, 50, 25, 12.5, 6.25, 3.125 g/ml. The final assay volume per 
well was 200 l and for each sample tested triplicates were performed. The cells were 
incubated for 24 h, and after optical judgement, the remaining adherent viable cells were 
stained by adding 100 l crystal violet solution (0.5% crystal violet in 20% methanol and 80% 
distilled water) for 15 minutes, washed in tap water, and air dried. Cell viability was quantified 
by measuring the absorbences at 540 nm using Titertek Multiscan plate-reader (Flow, 
Rockville, MD, USA). Cell survival is expressed as the percentage of the cells surviving 
relative to the number of cells of untreated control cultures. The killing rate was calculated 
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 using the following formula: 100%-% survival. EC50 implies the concentration of drug that 
resulted in 50% killing.  
 
3.6 Neurosphere culture  
In parallel to bulk cultures, CSC were isolated from glioblastoma tissue using neurosphere 
culture conditions as described from Galli and his colleagues [8]. CSC were cultivated in 75 
cm2 flask containing complete neurobasalmedium. They were incubated at 37° until they 
formed neurospheres measuring approximately 150 m. Neurospheres were splitted by 
using Trypsin-EDTA for 5 minutes, followed by the addition of 100 l trypsin inhibitor (10 
mg/ml, Sigma Aldrich). Thereafter, the cell suspension was filtered through a 30 m cell filter 
(Partec, Münster, Germany). After centrifugation (700rpm for 5 minutes), the cells were 
resuspended with medium and counted to prepare a suspension of 105 cells/ml. Afterwards, 
cells were distributed in 100l to 96-well F-plates (10.000 cells/well). 24 hours later, the CSC 
were treated with taurolidine, TT, TMZ, anti-CXCR1 antibody or recombinant IL-8. For each 
experiment, these agents were freshly prepared and diluted in complete neurobasalmedium. 
Taurolidine and TT were prepared at the concentrations of 1.56, 3.125, 6.25, 12.5 and 25 
g/ml. TMZ was concentrated between 5, 25, 250, 500 and 1000 M. The final concentration 
of anti-CXCR1 antibody was 2.5, 10 and 25 g/ml and recombinant IL-8 was 2.5, 10 and 25 
ng/ml. The final assay volumes per well were 200 l and each sample was tested at least 
three times. The cells were incubated for 7 days, and after optical judgement, 25 l 
AlamarBlue (Invitrogen, California, US) was added per well. After 3-4 hours, the 
fluorescence, as a dimension of viability, was measured on a fluorescence 
spectrophotometer (Cytofluor 2350, Witec AG, Littau, Switzerland) at an excitation of 590 nm 
and an emission of 530 nm. Cell survival, killing rate and EC50 were calculated using the 
same formula as described above.  
To compare the cytotoxicity of the mentioned agent on bulk cells, we treated the bulk cells in 
analogous way.  
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4. Results 
4.1 Dose- and time-dependent cytotoxicity of taurolidine and its derivates 
on different cell lines and ex vivo cultured glioblastoma cells 
 
 A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Taurolidine, 2012 and GS208 induced cytotoxicity in LN229 (A), U373 (B), U251 (C) glioma 
cells. 20.000 cells/well were treated for 24 hours and cytotoxicity was evaluated by crystal violet 
staining as described in Material and Methods. Data are presented as mean values ± SD of three 
independent experiments.  
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Six glioblastoma cell lines and two ex vivo glioblastoma cell cultures were tested for their 
sensitivity to taurolidine and its derivates (2012, GS208, TT, HG40, E1234, 2240, 1183A, 
1183BX) in the range of 3.125 g/ml to 800 g/ml. Figure 3 demonstrates the percentages of 
cells that were killed (killing%) after 24 hours of exposure to taurolidine and its derivates 
2012 and GS208 in cell lines LN229, U373, U251. As shown in Figure 3, cytotoxicity of these 
agents displayed a dose-dependency. 
 
In these cytotoxicity assays the effective concentration of taurolidine required to kill 50% of 
the cells (EC50) was remarkable lower than EC50 of 2012 and GS208 (Fig. 4A). An increase 
of the exposure-time to 48 hours did not reduce EC50 significantly (Fig. 4B). 
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Figure 4. EC50 of taurolidine, 2012, GS208 in LN229, U373 and U251. Cytotoxicity was assessed after 
24 h (A) and 48 h (B) of treatment. Data are shown as mean values of three individual experiments. 
ND=not done.  
 
 
Remaining derivatives which were tested (TT, 1183A, 1183BX) are presented in Figure 5. 
EC50 of TT is comparable with the value of taurolidine. To answer the question of whether 
freshly isolated human glioblastoma cells are also sensitive to taurolidine or to any of its 
derivates, we established cell cultures of two freshly resected tumour tissues and performed 
cytotoxicity assays. Also freshly isolated human glioblastoma cells showed susceptibility to 
taurolidine and TT in a similar range (Fig. 5). 
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Figure 5. EC50 of taurolidine, TT, 1183A, 1183BX in LN229, U373, U251, GBM #1 and GBM #2. 
Cytotoxicity was measured after 24 hours and data are shown as mean values of three individual 
experiments.  
 
 
The overview of Table 1 demonstrates that EC50 of taurolidine after an exposure time of 24 
hours was always less than 100 g/ml. The mean EC50 was 45 ± 24 g/ml and the EC50 
ranged from 30 g/ml for U373 and U251, the most sensitive cell lines, to 90 g/ml for U87G, 
the most resistant cell line. The mean EC50 of TT was 101 ± 100 g/ml, ranging from 37 
g/ml for the most sensitive cell line LN229, to 260 g/ml for T98G, the most resistant cell 
line. The mean EC50 of 2012, GS208, 1183A and 1183BX always exceeded 100 g/ml 
noticeable. At the maximal concentration of 800 g/ml HG40, E1234 and 2240 were not able 
to induce a killing rate of 50%, therefore their EC50 could not be calculated. For the ex vivo 
glioblastoma cultures that we have tested, taurolidine and TT were again the most powerful 
agents. The mean EC50 of taurolidine was 36 ± 38 g/ml and the mean EC50 of TT was 45 ± 
25g/ml. The two ex vivo GBM were also sensitive to 2012 with an EC50 of 45 ± 48 g/ml. 
1183A and 1183BX had an EC50 greater than 75 g/ml.  
 Table 1. Cytotoxicity of taurolidine and its derivates on human glioma cells after 24 and
48 hours of treatment
cell line Cytotoxicityª
    EC50(g/ml) 24 hb
n Tau TT 2012 GS208 HG40 E1234 2240 1183A 1183BX
LN229 11 35 37 120 145 >800 >800 >800 230 220
U373 3 30 47 90 100 >800 >800 >800 230 195
U251 3 30 60 98 220 >800 >800 >800 220 110
T98G 3 38 260 155 200 >800 >800 >800 380 360
LN18 3 50 ND 110 195 >800 >800 >800 NDc ND
U87G 2 90 ND 380 390 >800 >800 >800 ND ND
mean ± SD 45 ± 24  112 ± 100 158  ± 111 208 ± 99 n.a.d n.a. n.a 265 ± 77 221 ± 104
GBM #1 3 9 27 11 ND ND ND ND 100 12
GBM #2 3 63 63 80 ND ND ND ND 160 140
mean ± SD 36 ± 38 45 ± 25 45 ± 48 130 ± 42 76 ± 90
cell line Cytotoxicity
EC50(g/ml) 48 h
n Tau TT 2012 GS208 HG40 E1234 2240 1183A 1183BX
LN229 3 28 ND 78 80 >800 >800 >800 ND ND
U373 3 9 ND 145 150 >800 >800 >800 ND ND
ª Cytotoxicity was assessed after 24 and 48 h of treatment by crystal violet staining
b EC50 = effective concentration resulting in 50% cell death compared to untreated control cultures
c ND = not done
d n.a. = not applicable
 
4.2 Influence of the caspase inhibitor Z-VAD-FMK and the radical 
scavenger NAC on taurolidine- and TT- induced cell death 
In previous studies it was shown that N-acetyl-L-cysteine (5 mM), a precursor of glutathione, 
prevents taurolidine- induced cell death. This protective effect is explained by its nucleophilic 
and antioxidant properties. Therefore it is supposed that taurolidine induces cell killing by 
induction of reactive oxygen intermediates (ROI) [16, 19].  
We confirmed the protective effect of NAC, added at a concentration of 5 mM 20 minutes 
before treatment. The killing induced by 25 g/ml and 50 g/ml taurolidine was reduced by 
89% respectively 81% in LN229 glioma cell line (Fig. 6A). Cell killing induced by a high 
concentration of 100 g/ml taurolidine could not be prevented. Furthermore, we 
demonstrated that killing induced by 25 g/ml TT in the same cell line was likewise 
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 decreased by 68%, but there was no remarkable protective effect of NAC at the killing 
induced by 50 g/ml and 100 g/ml TT (Fig. 6B).  
Z-VAD-FMK is a pan-caspase inhibitor that can inhibit induction of apoptosis by binding 
irreversibly to the effector caspases. It is known that apoptosis induced by FasL is completely 
inhibited when Z-VAD-FMK was added to the cells one hour before treatment at a 
concentration of 50 M. As recently shown in our laboratory caspase activation is not 
required for taurolidine- induced cell death of glioma cells [19]. 
Our results verify the presumption that Z-VAD-FMK (10 M) had no influence neither on 
taurolidine- nor on TT- induced cytotoxicity. It minimizes the killing induced by 50 g/ml 
taurolidine on the LN229 glioma cell line maximal at 10% and there was no reduction of cell 
death induced by TT (Fig. 6B). To proof the protective effect of Z-VAD-FMK on caspase-
dependent cell death, we treated the same cell line, after adding Z-VAD-FMK at a 
concentration of 10 M, with Mega FasL at various concentrations (5 to 500 ng/ml). As 
shown in Figure 6C, Z-VAD-FMK prevented apoptosis induced by Mega FasL completely at 
all concentrations investigated.  
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Figure 6. The radical scavenger NAC, but not the pan-caspase inhibitor Z-VAD-FMK prevents 
taurolidine- or TT- induced killing. The LN229 glioma cells were pretreated with Z-VAD-FMK (10M) 
for 60 minutes or NAC (5mM) for 20 minutes and then left untreated or exposed to taurolidine (A), TT 
(B) and Mega FasL (C) for 24 h. Data are given as mean values ± SD of three independent 
experiments.  
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Figure 7. Phase contrast photo-micrographs demonstrating the cytotoxicity induced by taurolidine, TT 
and Mega FasL on LN229. The cells were left either untreated or pretreated with Z-VAD-FMK (10 M) 
or NAC (5mM) before taurolidine or TT exposure (50 g/ml) for 24h.  
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4.3 Time- and dose- dependent cytotoxicity of taurolidine and TT on 
mouse bulk and cancer stem cells 
Murine SMA 560 bulk cells were treated with various concentrations of taurolidine and TT 
(6.25, 12.5, 25, 50, 100, 200 g/ml) and cytotoxicity was determined after 24 and 48 hours. 
As shown in Figure 8, cytotoxicity of taurolidine and TT on SMA 560 bulk cells displayed a 
dose-dependency, but non remarkable time-dependency. The EC50 was 19.3 g/ml for TT 
and 34.6 g/ml for taurolidine and did not significantly change between 24 and 48 hours of 
treatment.  
A  
 
 
 
 
 
 
 
 
 
 
 
B  
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Figure 8. Cytotoxicity in SMA 560 bulk glioma cells after treatment with taurolidine and TT. 
Cytotoxicity was assessed after 24 h (A) and 48 h (B) of treatment. EC50 of taurolidine and TT in the 
same cell line (C). Data are presented as mean values ± SD of three independent experiments.  
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After the in vitro generation of CSC from SMA 560, we treated them with taurolidine and TT 
at the same concentrations (6.25, 12.5, 25, 50, 100, 200 g/ml). After 7 days of exposure to 
these agents, cytotoxicity was measured using the AlamarBlue assay. Figure 9 shows that 
taurolidine and TT generate a dose-dependent cytotoxicity on CSC as well. EC50 of TT was 
10 g/ml whereas taurolidine reached EC50 at a concentration of 12.5 g/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Cytotoxicity of taurolidine and TT on murine SMA 560 glioma CSC. Data are presented as 
mean values ± SD of two independent experiments.  
 
 
4.4 Taurolidine and TT induce cell death on human CSC of four different 
glioblastoma patients 
Based on our findings that taurolidine and TT induce cell death of murine CSC, we treated ex 
vivo human CSC, isolated from glioblastoma tissue as recently described by Galli et al [8]. 
The same range of concentrations of taurolidine and TT were applied and the cytotoxicity 
was measured after 7 days of incubation. Figure 10 demonstrates that all glioblastoma CSC 
(GBM #3, #4, #5 and #6) were sensitive to taurolidine and TT. The mean EC50 of taurolidine 
was 13 ± 2 g/ml, whereas the mean concentration of TT resulting in 50% cell death was 11 
± 0.9 g/ml. 
We compared the cytotoxic capacity of taurolidine and TT with TMZ on the same four GBM 
CSC at various concentration of TMZ between 5 M to 1000 M. The EC50 of TMZ were in 
the range of 220 to 500 M, corresponding to a concentration range of 46 to 97 g/ml. The 
average EC50 was 68.5 ± 26 g/ml. Interestingly, this concentration was much higher than 
peak plasma levels of TMZ in patients which was determined to be 13.7 g/ml (=115 M) 
[25]. 
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Table 2. In vitro effect of taurolidine, TT and TMZ on CSC derived from four different glioblastoma 
patients. 
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Figure 10. Cytotoxicity induced in CSC of 4 GBM patients (GBM #3, #4, #5 and #6) after treatment 
with taurolidine (A), TT (B) and TMZ (C). Cytotoxicity was measured after 7 days of treatment with 
AlamarBlue. Data are presented as mean values ± SD of two to three independent experiments.  
CSC Cytotoxicityª
    EC50 (?g/ml) 24 h
b
n Tau TT TMZ
GBM #3 3 15 10.5 84.4 (435 μM)
GBM #4 2 12.5 12.5 97 (500 μM)
GBM #5 2 14 11 48.5 (250 μM)
GBM #6 3 10 9 44 (230 μM)
mean ± SD 13 ± 2 11 ± 1.4 68.5 ± 26
ª Cytotoxicity was assessed after 7 days of treatment by AlamarBlue.
b EC50 = effective concentration resulting in 50% cell death compared 
to untreated control cultures.
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Figure 11. Phase contrast photomicrographs demonstrating the cytotoxicity induced by tauroldine, TT 
and TMZ on CSC of GMB #6. The cells were left either untreated or treated for 7 days. Bar=100 m. 
 
 
4.5 Comparison of the EC50 of taurolidine, TT and TMZ on bulk versus 
CSC of GBM #3 
To address the question whether bulk and CSC of the same ex vivo glioblastoma show 
similiar or different susceptibility to the agents we have tested above, we treated bulk and 
CSC of GBM #3 with taurolidine, TT and TMZ for four days. As shown in Figure 12, CSC 
were more sensitive to TT and TMZ. The EC50 of CSC is reduced for TT by 51%, for TMZ by 
60%, whereas for taurolidine the concentration required to kill 50% of the CSC is increased.  
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Figure 12. EC50 of taurolidine, TT and TMZ in bulk and CSC of GBM #3. Data are shown as mean 
values of three individual experiments.  
 
 
4.6 Influence of anti-CXCR1 antibody treatment on human CSC 
A recently published study reported that IL-8 receptor blockade selectively targets breast 
cancer stem cells [24]. In 1997, it was published that IL-8 is up regulated in brain tumour 
tissue [23]. Therefore, we treated CSC from GBM #3, #4 and #5 with anti-CXCR1 antibody at 
concentrations of 2.5, 10 and 25 g/ml. Thereafter, the cells were incubated for 7 days and 
the cytotoxic effect evaluated. As presented in Figure 11, the antibody treatment induced in 
GBM #5 about 25% cell death. In the other tested GBM no killing effect has been found.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Cytotoxicity in CSC from three different glioblastoma patients (GBM #3 #4 and #5) after 
treatment with anti-CXCR1 antibody, measured after seven days with AlamarBlue. Data are presented 
as mean values ± SD of three independent experiments. 
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4.7 Influence of recombinant IL-8 on the proliferation of human CSC 
Since we had no cell death after blocking CXCR1 in GBM #3 and #4, but cell killing induction 
in GBM #5, we treated GBM #3 and GBM #5 with recombinant IL-8 at concentrations of 2.5, 
10 and 50 ng/ml to investigate if external IL-8 would activate the proliferation of human CSC. 
Figure 14 shows that recombinant IL-8 did neither in GBM #3 nor in GBM #5 stimulate the 
proliferation. To see whether the negative findings could be explained by the lack of the IL-8 
receptor we performed immunofluorescence staining (Fig. 15). As shown in Figure 15, not 
only CSC (spheres) but also glioblastoma tumour tissue showed a CXCR1 expression of 20-
30%. 
 
 
 A  
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Figure 14. Stimulation of CSC from GBM #3 (A) and GBM #5 (B) after treatment with recombinant IL-
8. Proliferation was assessed after 2, 5 and 7 days with the AlamarBlue assay.  
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Figure 15. CXCR1 protein expression in spheres and tissue of glioblastoma (GBM #6). Spheres 
grown on cover slips and stained with anti-CXCR1 (A). Frozen sections of tumour tissue, labeled with 
anti-CXCR1 (B). Frozen sections of tumour tissue, labeled with an isotype control (IgG2a) (C). DAPI 
was used to stain cell nuclei. Bars: 20 m.  
 5. Discussion 
 
Despite ongoing research, glioblastoma multiforme are still resistant to current surgery, 
chemo- and radiotherapy. With this study we continued the ongoing research of our 
laboratory on the antineoplastic activitiy of taurolidine on glioblastoma cells. The goal was to 
investigate the most powerful derivatives of taurolidine, which were still unknown. We tested 
taurolidine and eight derivatives on glioma cell lines and ex vivo glioblastoma cells. In 
addition, we tested the chemosensitivity of cancer stem cells isolated from glioblastomas.  
 
Isolation of the most powerful derivatives 
In the first part of this thesis we assessed the antineoplastic potential of taurolidine and 
all its breakdown products on several glioma cell lines and ex vivo cultured glioblastoma 
cells. We performed a number of cytotoxicity assays, measuring the susceptibility to these 
agents. We found that all tested glioblastoma cell lines were sensitive to taurolidine, reaching 
a mean EC50 of 45 g/ml. With a mean EC50 of 101 g/ml taurultam (TT) posses the highest 
antineoplastic activity of all intermediates tested. All other derivates were less potent and had 
therefore a considerably higher EC50. The results for ex vivo glioblastoma cells were similar. 
Therefore, we assume that TT is mainly responsible for the antineoplastic activity of 
taurolidine. Bearing in mind that in previous reports on clinical applications of taurolidine the 
plasma concentrations of taurolidine (or its initial derivatives) ranged from 20 to 100 g/ml in 
patients with septicaemia whereas in healthy volunteers taurolidine was examined in a 
concentration range of 5 to 100 g/ml [19] and knowing that except for one cell line EC50 of 
taurolidine and TT was lower than 60 g/ml, we assume that not only taurolidine but also TT 
are promising therapeutic agents. Since first case reports of intravenous taurolidine 
treatment in patients with progressive GBM showed a transient improvement in patients’ 
quality of life and partial tumour remission [26], further clinical investigations should be 
aspired. At the moment encapsulated taurolidine is under clinical investigation with the 
advantage of a per oral application. 
 
Cell killing mechanism of taurolidine and TT  
Our findings are in accordance with earlier experiments performed in our laboratory by 
Rodak, et al [19] who demonstrated that the pan-caspase inhibitor Z-VAD-FMK, which 
protects cells completely from FasL-induced apoptosis, did not greatly influence taurolidine- 
induced cell death of GBM cells. They further proofed that cell death induced by taurolidine 
can be inhibited by a coincubation with the radical scavenger NAC and concluded that 
taurolidine induce cell killing by formation of reactive oxygen intermediates (ROI). Further 
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 investigations on this topic showed that oxidative cell damage leads to several cell death 
pathways such as autophagy, senescene, necroptosis and necrosis [5].  
Our results confirm the assumption that TT and all the other derivatives are inducing the 
same cell death mechanism as taurolidine, namely causing oxidative cell damage as NAC, 
but not Z-VAD-FMK prevented TT- induced cell death. From the fact that NAC is not able to 
inhibit cell death induced by TT, concentrations higher than 50 g/ml, leads to the question 
whether additional mechanism of cell death are involved. A recently published study that 
performed a comparative analysis of cell death induction by taurolidine simultaneously in 
different malignant cell lines proofed that taurolidine provides multifaceted cell death 
mechanism leading to a cell line specific diversity [27]. 
 
Cytotoxicity on CSC and comparision to the effect of TMZ 
In the second part of this thesis we examined the chemosensitivity of freshly isolated 
glioblastoma CSC to taurolidine and TT. Our findings revealed that all CSC were sensitive to 
taurolidine and TT. The EC50 of both agents were in the range of the measured plasma level 
of taurolidine. In contrast the EC50 of TMZ on CSC was higher than its peak plasma level. 
The 2-fold higher EC50 of GBM #3 and #4 is probably due to their non methylated MGMT 
status. 
Based on these findings we wanted to compare the susceptibility of CSC versus bulk tumour 
cells. Our results have shown that CSC are more sensitive to taurolidine and TT than bulk 
cells. Interestingly, TMZ was also more potent on CSC which is in accordance with a study 
published by Beier, et al [16]. The reason for the preferential depletion of CSC is not 
elucidated until now. These findings will be evaluated in future experiments in an orthotopic 
glioma mouse model using SMA 560 CSC and bulk cells. 
 
Impact of CXCR1 targeting by antibodies or IL-8 on CSC 
Recently it has been reported that blockage of CXCR1 by an antibody or by the 
pharmacological inhibitor repertaxin induced CSC death in breast cancer tissue. From the 
fact that glioblastoma cells are expressing IL-8 and their corresponding receptors, we 
examined the influence of anti-CXCR1 antibody on CSC. One out of three tested CSC 
showed a significant cell death whereas the others were resistant. In another set of 
experiments we tested whether IL-8 added to the CSC cultures could increase the sphere 
initiation capacity. From the fact that this was not the case, we analyzed CSC on their 
CXCR1 expression by confocal microscopy laser scanning and found a substantial number 
of positive cells. This suggests that the signalling pathway in CSC of GBM might be different 
than in CSC of breast cancer.  
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 Taken together, our study showed that taurultam is the most powerful derivative of 
taurolidine among the eight tested ones and induces cell death in glioblastoma bulk and CSC 
by causing oxidative damage leading to cell death. Since all four CSC of the glioblastomas 
tested are more sensitive than the bulk cells to taurolidine and TT and chemoresistance of 
CSC is responsible for the recurrence of GBM, taurultam should be investigated in a clinical 
trial.  
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